Archives
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
CGP 55845 hydrochloride The synthetic route to M developed b
2024-10-30

The synthetic route to M100907 developed by Rice was utilized, however, the chiral resolution was carried out at an earlier stage to provide the possibility of introducing different substituents onto the piperidinyl group. The conditions for this resolution were different from previously reported.
-
Does dietary caffeine interfere with antinociception by othe
2024-10-30

(8) Does dietary caffeine interfere with antinociception by other modalities that alter pain (TENS, exercise, joint mobilization, water immersion therapy)? Caffeine and/or A1R antagonists inhibit antinociception by each of these modalities in preclinical studies, such that there is potential for int
-
To date more than different
2024-10-29

To date, more than 50 different mutations in the gene have been described (Human Gene Mutation Database at the Institute of Medical Genetics in Cardiff: SRD5A2 Gene: http://www.hgmd.cf.ac.uk). Most of them are missense mutations but premature stop codons and deletions leading to non-functional or su
-
Application of the broad acting HTR antagonist methiothepin
2024-10-29

Application of the broad-acting 5-HTR antagonist methiothepin (Bard et al., 1996, Hoyer et al., 1994, Peroutka, 1990) converted the TBS-induced response of both thalamocortical and intracortical A1 synapses from LTP to LTD, an effect that was mimicked by the selective 5-HT2R antagonist ketanserin (L
-
Matsuzaki et al attempted fertility therapy in a year
2024-10-29

Matsuzaki et al. attempted fertility therapy in a 26-year-old female with secondary amenorrhea and 17OHD who was a UNC1215 sale heterozygote for delF53/54 and the missense mutation H373L, which has cycle supports this theory. Oocyte dysfunction with decreased granulosa cell activity might also con
-
In our H K ATPase assay Fig and Supplementary
2024-10-29

In our H+, K+-ATPase assay (Fig. 1 and Supplementary Fig. 1), myricetin (IC50 = 0.58μM) was more potent than acid-activated omeprazole (IC50 = 1.50μM). In contrast, in oral administration in mice (Fig. 3), omeprazole (20mg/kg) more effectively inhibited gastric what is doxycycline hyclate secretion
-
We conclude that Tetrapleura tetraptera fruits extract
2024-10-29

We conclude that Tetrapleura tetraptera fruits extract possess antiplasmodial activity and the results of this study justifies and confirms the traditional usage of this plant as malarial remedy. Acknowledgement Introduction The phylum apicomplexa comprises of nearly 5000 species, most of whi
-
br HIF Blockade in AA Therapy In lieu of
2024-10-29

HIF-α Blockade in AA Therapy In lieu of the evidence supporting a central role for HIF-α signaling in tumor angiogenesis and CC pathobiology, significant efforts have focused on the discovery of small-molecule HIF-α inhibitors (for exhaustive compendia, see [28,44,45]). In brief, inhibitors vary
-
Current treatment options for corneal neovascularization inc
2024-10-29

Current treatment options for corneal neovascularization include topical application of steroids220, 25, 35, 43 or surgical interventions: laser ablation,14, 203, 234, 48 photodynamic therapy (PDT),4, 93 and fine-needle diathermy.221, 238, 240, 261 Targeting proangiogenic molecules with topical or s
-
The aldehyde reductase AKR A and aldose reductase AKR B
2024-10-28

The aldehyde reductase (AKR1A1) and aldose reductase (AKR1B1) belong to aldo-ketoreductase (AKR) superfamily catalyzing the reduction of corresponding aldehydes and ketones involved. Both the closely related enzymes AKR1A1 and AKR1B1 have 65% structural similarity and differ only at the active site.
-
Globally the total number of patients included in
2024-10-28

Globally, the total number of patients included in the meta-analysis was 1885, ranging from 40 to 442 patients per study. All eligible studies reported the association between ALDH1 expression and patients' OS [24-26, 3241], whereas nine studies evaluated the relationship between ALDH1 expression an
-
br Rapid nongenomic effects of corticosterone in
2024-10-28

Rapid nongenomic effects of corticosterone in an amphibian model Studies in the model organism, the roughskin newt, Taricha granulosa, over 30 years ago led to the discovery that stress can rapidly (within minutes) suppress sexual behavior (amplectic clasping) of male T. granulosa, an effect that
-
Our previous work fails to show any maternal effect with
2024-10-28

Our previous work fails to show any maternal effect with blockade of 5-HT2A receptor, as acute and repeated treatment of MDL100907 does not alter maternal behavior at the behaviorally active doses (Chen et al., 2014). In the present study, MDL100907 pretreatment attenuated the maternal disruptive ef
-
Phosphodiesterase inhibition increases the intracellular lev
2024-10-28

Phosphodiesterase inhibition increases the intracellular levels of cAMP to restore spontaneous contraction (Essayan, 2001, Qi and Kwan, 1996), acting downstream of adenylyl cyclase. Therefore, cardiac arrest induced by decreased intracellular cAMP levels could be reversed by phosphodiesterase inhibi
-
We also demonstrate that PACAP treatment dose dependently
2024-10-28

We also demonstrate that PACAP treatment dose-dependently disrupts performance in the 5CSRTT, suggestive of attentional deficits, another core feature of mood and anxiety disorders. Treatment with PACAP (.5–1.0 µg) decreased the percentage of correct responses, increased the percentage of trials in
15824 records 66/1055 page Previous Next First page 上5页 6667686970 下5页 Last page